We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.675 | -7.16% | 8.75 | 8.30 | 9.20 | 9.50 | 9.20 | 9.50 | 606,108 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.09 | 23.2M |
TIDMC4XD
RNS Number : 5868Q
C4X Discovery Holdings PLC
30 November 2016
30 November 2016
This announcement contains inside information
C4X Discovery Holdings plc
("C4XD" or the "Company")
DIRECTOR'S DEALING
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, announces that Dr. Clive Dix, Chief Executive Officer, has today purchased 40,000 ordinary shares of 1 pence each ("Ordinary Shares") a price of GBP0.97 pence per Ordinary Share.
Director Ordinary Ordinary Interest Interest Total Shares Shares in issued in Ordinary interest held prior purchased share Shares via in issued to dealing capital incentive share (%) arrangements capital (%) ------------- ------------ ----------- ---------- -------------- ----------- Dr. Clive Dix, Chief Executive Officer 1,156,936 40,000 3.20% 145,000 3.59% ------------- ------------ ----------- ---------- -------------- -----------
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated ---- ------------------------------------------------------------------------------------------------ a) Name Dr. Clive Dix ---- ------------------------------------------------------------ ---------------------------------- 2 Reason for the notification ---- ------------------------------------------------------------------------------------------------ Chief Executive Officer, Director a) Position/status ---- ------------------------------------------------------------ ---------------------------------- b) Initial notification/Amendment Initial Notification ---- ------------------------------------------------------------ ---------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---- ------------------------------------------------------------------------------------------------ a) Name C4X Discovery Holdings plc ---- ------------------------------------------------------------ ---------------------------------- b) LEI N/A ---- ------------------------------------------------------------ ---------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---- ------------------------------------------------------------------------------------------------ a) Description of the financial instrument, type of instrument 1p ordinary shares Identification code ISIN GB00BQQ2RV18 ---- ------------------------------------------------------------ ---------------------------------- b) Nature of the transaction Purchase of Ordinary Shares ---- ------------------------------------------------------------ ---------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ---------- ---------- GBP0.97p 40,000 ---------- ---------- ---- ------------------------------------------------------------ ---------------------------------- d) Aggregated information Price(s) Volume(s) ---------- ---------- GBP0.97p 40,000 ---------- ---------- ---- ------------------------------------------------------------ ---------------------------------- e) Date of the transaction 30 November 2016 ---- ------------------------------------------------------------ ---------------------------------- f) Place of the transaction London Stock Exchange - AIM ---- ------------------------------------------------------------ ----------------------------------
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Zeus Capital Limited
Dan Bate
0161 831 1512
Dominic Wilson/Phil Walker
0203 829 5000
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709 5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4X's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. This provides new and unprecedented insight into the behaviour of drug molecules, enabling the production of potent selective compounds faster and more cost effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. In selecting new targets C4X Discovery will focus on the high-value disease areas of inflammation and neurodegeneration, and will continue to maximise value from opportunistic areas, for example, immuno-oncology.
The Company was founded as a spin-out from the University of Manchester. It has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4X to reach multiple value inflexion points since IPO. For additional information please go to: www.c4xdiscovery.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEALFEDAAKFFF
(END) Dow Jones Newswires
November 30, 2016 09:25 ET (14:25 GMT)
1 Year C4x Discovery Chart |
1 Month C4x Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions